New drug combo shows promise for advanced liver cancer
NCT ID NCT03519997
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs, pembrolizumab and bavituximab, in people with advanced liver cancer that cannot be treated with surgery or local therapies. About 35 participants will receive the treatment to see how many respond and how safe it is. The goal is to find a better option for those who have not had prior systemic therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parkland Health & Hospital System
Dallas, Texas, 75235, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.